Pathomorphological and molecular genetic features of diffuse gastric cancer

 Gastric cancer (GC) is the 5th most common type of cancer in the world and the third leading cause of death from cancer. GC is a multi-factorial and morphologically heterogeneous disease. Currently, several morphological classifications of GC are used, however, for diagnosis, it is necessary to take into  account not only the morphological type of the tumor, but also its molecular subtype. According to the literature, the intestinal type of GC is most often associated with effects of environmental factors and is usually found in older  age groups in men, while diffuse gastric cancer (DGC) is a genetically determined disease which is more common in younger patients, with the same 
frequency among men and women.
This review covers in detail GC, its classification by P.A. Lauren (1965), and its molecular subtypes characterized during the Cancer Genome Atlas project and examines the impact of certain risk factors on the pathogenesis of the disease, such as: H. pylori infection or Epstein – Barr virus. A separate section in this analytical work is dedicated to expression of the PD-L1 marker by tumor cells and the use of this parameter for prognosis and therapy of this disease. An essential part of the work is discussion of the features of intestinal and diffuse types of gastric cancer, which reflect not only the differences in classifications used in modern diagnosis, but also the relationship between the pathological pattern and the molecular subtype of gastric cancer. 

1. Cancer incidence in five continents. IARC Press, 1996.

2. Злокачественные новообразования в России в 2018 году; под ред. А.Д. Каприна, В.В. Старинского, Г.В, Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019: 250.

3. Laurén P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol. Microbiol. Scand. 1965; 64: 31–49. DOI: 10.1111/apm.1965.64.1.31.

4. Binh T.T., Tuan V.P., Dung H.D.Q., Tung P.H., Tri T.D., Thuan N.P.M., Khien V.V., Hoan P.Q., Suzuki R., Uchida T. et al. Advanced non-cardia gastric cancer and Helicobacter pylori infection in Vietnam. Gut Pathog. 2017; 9: 46. DOI: 10.1186/s13099-017-0195-8.

5. Correa P. Human gastric carcinogenesis: A multistep and multifactorial process-first American Cancer Society award lecture on cancer epidemiology and prevention. Cancer Res. 1992; 52 (24): 6735–6740.

6. Fischbach W., Chan A., Wong B. Helicobacter pylori and gastric malignancy. Helicobacter. 2005; 10: 34–39. DOI: 10.1111/j.1523-5378.2005.00338.x.

7. Белкофец А.В., Решетников О.В., Курилович С.А., Максимов В.Н. Рак желудка: современные молекулярно-генетические данные (обзор литературы). Сибирский онкологический журнал. 2014; 2 (62): 56–64.

8. World cancer report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015.

9. Bass A., Thorsson V., Shmulevich I., Reynolds S.M., Miller M., Bernard B. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014; 513 (7517): 202–209. DOI: 10.1038/nature13480.

10. Grinstein S., Preciado M.V., Gattuso P., Chabay P.A., Warren W.H., De Matteo E., Gould V.E. Demonstration of Epstein-Barr virus in carcinomas of various sites. Cancer Res. 2002 Sept. 1; 62 (17): 4876–4878.

11. Tajima M., Komuro M., Okinaga K. Establishment of Epstein-Barr virus-positive human gastric epithelial cell lines. Jpn J. Cancer Res. 1998; 89 (3): 262–268. DOI: 10.1111/j.1349-7006.1998.tb00557.x

12. Zhang Y., Molot R. Severe gastritis secondary to Epstein-Barr viral infection. Unusual presentation of infectious mononucleosis and associated diffuse lymphoid hyperplasia in gastric mucosa. Arch. Pathol. Lab. Med. 2003; 127 (4): 478–480. DOI: 10.1043/0003-9985(2003)127.

13. Uozaki H., Fukayama M. Epstein-Barr virus and gastric carcinoma – viral carcinogenesis through epigenetic mechanisms. Int. J. Clin. Exp. Pathol. 2008; 1 (3): 198–216.

14. Кононов А.В. Гетерогенность воспалительного ответа в популяции при Helicobacter pylori-инфекции. Педиатрия. 2002; 2: 124–130.

15. Кононов А.В. Молекулярно-клеточные основы взаимодействия Helicobacter pylori и хозяина. Инфект удален – что дальше? Омский научный вестник. 2002; 21: 17–28.

16. Кононов А.В., Мозговой С.И., Ливзан М.А., Предвечная И.К., Новикова Л.Д. Обратное развитие морфологических признаков при основных вариантах хронического гастрита в условиях эрадикации Helicobacter pylori. Архив патологии. 2005; 67 (3): 17–21.

17. Boland C.R., Thibodeau S.N., Hamilton S.R., Sidransky D., Eshleman J.R., Burt R.W., Meltzer S.J., RodriguezBigas M.A., Fodde R., Ranzani G.N., Srivastava S. A National Cancer Institute Workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998; 58 (2): 5248–5257.

18. Corso G., Pedrazzani C., Marrelli D., Pascale V., Pinto E., Roviello F. Correlation of microsatellite instability at multiple loci with long-term survival in advanced gastric carcinoma. Arch. Surg. 2009; 144 (8): 722–727. DOI: 10.1001/archsurg.2009.42.

19. Geigl J., Obenauf A.C., Schwarzbraun T., Speicher M.R. Defining ‘chromosomal instability. Trends Genet. 2008; 24 (2): 64–69. DOI: 10.1016/j.tig.2007.11.006.

20. Mamalis A., Garcha M., Jagdeo J. Targeting the PD-1 pathway: a promising future for the treatment of melanoma. Arch. Dermatol. Res. 2014; 306 (6): 511–519. DOI: 10.1007/s00403-014-1457-7.

21. Boger C., Behrens H.M., Mathiak M., Kruger S., Kalthoff H., Rocken C. PD-L1 is an independent prognostic predictor in gastric cancer of Western patients. Oncotarget. 2016; 7 (17): 24269–24283. DOI: 10.18632/oncotarget.8169.

22. Chang H., Jung W.Y., Kang Y., Lee H., Kim A., Kim H.K., Shin B.K., Kim B.H. Programmed death-ligand 1 expression in gastric adenocarcinoma is a poor prognostic factor in a high CD8+ tumor infiltrating lymphocytes group. Oncotarget. 2016; 7 (49): 80426–80434. DOI: 10.18632/oncotarget.12603.

23. Kawazoe A., Kuwata T., Kuboki Y., Shitara K., Nagatsuma A.K., Aizawa M., Yoshino T., Doi T., Ohtsu A., Ochiai A. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients. Gastric Cancer. 2017; 20 (3): 407–415. DOI: 10.1007/s10120-016-0631-3.

24. Ma C., Patel K., Singhi A.D., Ren B., Zhu B., Shaikh F., Sun W. Programmed death-ligand 1 expression is common in gastric cancer associated with Epstein-Barr virus or microsatellite instability. Am. J. Surg. Pathol. 2016; 40 (11): 1496–1506. DOI: 10.1097/PAS.0000000000000698.

25. Derks S., Liao X., Chiaravalli A.M., Xu X., Camargo M.C., Solcia E., Sessa F., Fleitas T., Freeman G.J., Rodig S.J., Rabkin C.S., Bass A.J. Abundant PD-L1 expression in Epstein-Barr virus-infected gastric cancers. Oncotarget. 2016; 7 (22): 32925–32932. DOI: 10.18632/oncotarget. 9076.

26. Saito H., Kono Y., Murakami Y., Shishido Y., Kuroda H., Matsunaga T., Fukumoto Y., Osaki T., Ashida K., Fujiwara Y. Highly activated PD-1/PD-L1 pathway in gastric cancer with PD-L1 expression. Anticancer Res. 2018; 38 (1): 107–112. DOI: 10.21873/anticanres.12197.

27. Wang L., Zhang Q., Ni S., Tan C., Cai X., Huang D., Sheng W. Programmed death‐ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2‐negative status Cancer Med. 2018; 7 (6): 2612–2620. DOI: 10.1002/cam4.1502.

28. Fukamachi H., Kim S.K., Koh J., Lee H.S., Sasaki Y., Yamashita K. et al. A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors.

29. J. Exp. Clin. Cancer. Res. 2019; 38 (1): 127. DOI: 10.1186/s13046-019-1121-3.

30. Schistosomes, liver flukes and Helicobacter pylori. IARC working group on the evaluation of carcinogenic risks to humans. Lyon, 7–14 June 1994. IARC Monogr. Eval. Carcinog. Risks Hum. 1994; 61: 1–241.

31. IARC Helicobacter pylori working group. Helicobacter pylori eradication as a strategy for preventing gastric cancer. Lyon, France 2014: IARC working group reports, No. 8

32. Uemura N., Okamoto S., Yamamoto S., Matsumura N., Yamaguchi S., Yamakido M., Taniyama K., Sasaki N., Schlemper R.J. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 2001; 345 (11): 784–789. DOI: 10.1056/NEJMoa001999.

33. Komoto K., Haruma K., Kamada T., Tanaka S., Yoshihara M., Sumii K., Kajiyama G., Talley N.J. Helicobacter pylori infection and gastric neoplasia: correlations with histological gastritis and tumor histology. Am. J. Gastroenterol. 1998; 93 (8): 1271–1276. DOI: 10.1111/j.1572-0241.1998.00408.x.

34. Nishibayashi H., Kanayama S., Kiyohara T., Yamamoto K., Miyazaki Y., Yasunaga Y., Shinomura Y., Takeshita T., Takeuchi T., Morimoto K., Matsuzawa Y. Helicobacter pylori-induced enlarged-fold gastritis is associated with increased mutagenicity of gastric juice, increased oxidative DNA damage, and an increased risk of gastric carcinoma. J. Gastroenterol. Hepatol. 2003; 18 (12): 1384–13891. DOI: 10.1046/j.1440-1746.2003.03192.x.

35. Watanabe M., Kato J., Inoue I., Yoshimura N., Yoshida T., Mukoubayashi C., Deguchi H., Enomoto S., Ueda K.,

36. Maekita T., Iguchi M., Tamai H., Utsunomiya H., Yamamichi N., Fujishiro M., Iwane M., Tekeshita T., Mohara O., Ushijima T., Ichinose M. Development of gastric cancer in nonatrophic stomach with highly active inflammation identified by serum levels of pepsinogen and Helicobacter pylori antibody together with endoscopic rugal hyperplastic gastritis. Int. J. Cancer. 2012 Dec. 1; 131 (11): 2632–2642. DOI: 10.1002/ijc.27514.

37. Tatemichi M., Sasazuki S., Inoue M., Tsugane S. Clinical significance of IgG antibody titer against Helicobacter pylori. Helicobacter. 2009; 14 (3): 231–236. DOI: 10.1111/j.1523-5378.2009.00681.x.

38. Lee J.Y., Gong E.J., Chung E.J., Park H.W., Bae S.E., Kim E.H., Kim J., Do Y.S., Kim T.H., Chang H.S., Song H.J., Choe J., Jung H.Y. The characteristics and prognosis of diffuse-type early gastric cancer diagnosed during health checkups. Gut and Liver. 2017; 11 (6): 807–812. DOI: 10.5009/gnl17033.

39. Yang Y., Du J., Liu F., Wang X., Li X., Li Y. Role of caspase-3/E-cadherin in Helicobacter pylori-induced apoptosis of gastric epithelial cells. Oncotarget. 2017; 8 (35): 59204–59216. DOI: 10.18632/oncotarget.19471.

40. Oliveira M.J., Costa A.M., Costa A.C., Ferreira R.M., Sampaio P., Machado J.C., Seruca R., Mareel M., Figueiredo C. CagA associates with c-Met, E-cadherin, and p120-catenin in a multiproteic complex that suppresses Helicobacter pylori-induced cell-invasive phenotype. J. Infect. Dis. 2009; 200 (5): 745–755. DOI: 10.1086/604727.

41. Bagnoli F., Buti L., Tompkins L., Covacci A., Amieva M.R. Helicobacter pylori CagA induces a transition from polarized to invasive phenotypes in MDCK cells. Proc. Natl. Acad. Sci USA. 2005; 102 (45): 16339–16344. DOI: 10.1073/pnas.0502598102.

42. Lee H.E., Smyrk T.C., Zhang L. Histologic and immunohistochemical differences between hereditary and sporadic diffuse gastric carcinoma. Human Pathology. 2018; 74: 64–72. DOI: 10.1016/j.humpath.2017.12.023.

43. Wong H.H., Chu P. Immunohistochemical features of the gastrointestinal tract tumors. J. Gastrointest. Oncol. 2012; 3 (3): 262–284. DOI: 10.3978/j.issn.2078-6891.2012.019.